SavedAdd your journal

Journals / Klinik Psikofarmakoloji Bülteni / 2009 / Cilt: 19 - Sayı: 2

In perspective of meta-analyses: Are all of the antidepressants similar?

Meta-analizler ışığında: Bütün antidepresanlar aynı mıdır?

Cengizhan AÇIKEL
Mesut ÇETİN
Pages
87–92
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we will examine the latest systematic reviews and meta-analyses comparing effectiveness and tolerability of antidepressants

📌 3 Key Takeaways

🎯
Objective & Hypothesis:According to the World Health Organization (WHO) data and “the national disease burden and cost-effectiveness study” depression is the 4th cause of disease burden in Turkey.
📊
Key Findings & Data:During the last 20 years, prescription of antidepressants has risen dramatically in many western countries due to higher number of prescriptions of SSRIs and newer antidepressants, which have progressively become the most commonly prescribed antidepressants.
💡
Conclusion & Impact:In this article, we will examine the latest systematic reviews and meta-analyses comparing effectiveness and tolerability of antidepressants
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

According to the World Health Organization (WHO) data and “the national disease burden and cost-effectiveness study” depression is the 4th cause of disease burden in Turkey. During the last 20 years, prescription of antidepressants has risen dramatically in many western countries due to higher number of prescriptions of SSRIs and newer antidepressants, which have progressively become the most commonly prescribed antidepressants. SSRIs are generally better tolerated than tricyclic antidepressants (TCAs), and there is evidence that they work through similar mechanisms. In this article, we will examine the latest systematic reviews and meta-analyses comparing effectiveness and tolerability of antidepressants

Özet

Dünya Sağlık Örgütü (DSÖ) verilerine göre dünyada ve “Ulusal Hastalık Yükü ve Maliyet Etkililik” çalışması sonuçlarına göre Türkiye’de depresyon dördüncü hastalık yükü nedenidir. Bir çok Batı ülkesinde, son 20 yılda, antidepresan kullanımı dramatik bir şekilde artmıştır. Bu durum seçici serotonin gerialım inhibitörlerinin kullanımının ve daha yeni antidepresanların giderek daha yaygın reçetelenmesine bağlıdır. Seçici serotonin gerialım inhibitörleri trisiklik antidepresanlara göre genellikle daha iyi tolere edilmektedirler ve etkinliklerinin benzer olduğuna dair kanıtlar vardır. Bu yazıda antidepresanların etkinlik ve kabul edilebilirliklerini karşılaştıran son dönemlerdeki derleme ve meta-analizleri inceleyeceğiz

🔖

Cite This Article

AÇIKEL, C., ÇETİN, M. (2022). In perspective of meta-analyses: Are all of the antidepressants similar?. Klinik Psikofarmakoloji Bülteni, Cilt: 19 - Sayı: 2, 87–92. https://ajindex.com/articles/574303

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. WHO, Depression (2003), online erişim www.who.int/mental_health/management/depression/definition/en, 8 Mayıs 2009
  2. WHO, Preventing Suicide: A Resource for Primary Health Care Workers (2000), online erişim www.who.int/mental_health/ resources/suicide/en/, 8 May 2009
  3. RSHMB Hıfzıssıhha Mektebi Müdürlüğü, Ulusal Hastalık Yükü ve Maliyet-Etkililik Projesi, ARALIK 2004
  4. Trivedi MH., Treating depression to full remission. J Clin Psychiatry 2009;70[1]:e01. doi:10.4088/JCP.8017br6c.e01 5. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs. 2007;21:473-81
  5. Çırakoğlu OC, Uluç S, Uluç BN, Üniversite Öğrencileri Depresif Belirtileri Nasıl Algılıyor? Depresyonun Algılanan Nedenleri, Çareleri ve Yardım Davranışları Üzerine Niteliksel Bir Çalışma, TAF Prev Med Bull. 2008; 7: 119-126
  6. Yüksel N Antidepresan İlaçlar. Psikofarmakoloji. Ankara, Çizgi Tıp Yayınevi, 2003,169-264
  7. E. Onur, B. Yemez, S. Polat, N. Y. Gürz, C. Cimilli, Change in the preference of the psychotropic drugs and consultation liaison psychiatry practice, Klinik Psikofarmakoloji Bulteni, 2007, 2007;17:167-173 9. Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR., Are all antidepressants really the same? The case of fluoksetine: a systematic review. J Clin Psychiatry. 2006 Jun;67:850-64
  8. Nelson JC, Portera L, Leon AC., Assessment of outcome in depression. J Psychopharmacol. 2006;20(4 Suppl):S47-S53 11. Bagby RM, Ryder AG, Schuller DR, Marshall MB., The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry, 2004 Dec;161:2163-77
  9. Zimmerman M, Chelminski I, Posternak M., A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol. 2004;19:1-7
  10. Kadouri A, Corruble E, Falissard B. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry 2007, 7:7doi:10.1186/1471-244X-7-7 14. Cipriani A, Geddes JR, Furukawa TA, Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry. 2007;52:553-62
  11. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA, Efficacy and tolerability of milnacipran in the treatment of major depression in comp